Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-03 · accession 0000950170-24-002280 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-01-04 | 2024-01-03+ | DYN | Brumm Joshua T | CEO, Pres | M - OptEx | $4.37 | +269.7K | 803.5K | +51% | +$1.18M |
| DMT | 2024-01-04 | 2024-01-03+ | DYN | Brumm Joshua T | CEO, Pres | S - Sale+OE | $18.66 | -269.7K | 585.0K | -32% | -$5.03M |
| DMT | 2024-01-04 | 2024-01-03+ | DYN | Brumm Joshua T | CEO, Pres | M - OptEx | $0.00 | -269.7K | 107.9K | -71% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-03 | M | A | 51,183 | $1.03 | 636,154 | D | — | — | (F1) Includes 552,729 unvested RSUs. |
| 2 | Common | Common Stock | 2024-01-03 | S | D | 15,382 | $18.34 | 620,772 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. (F1) Includes 552,729 unvested RSUs. |
| 3 | Common | Common Stock | 2024-01-03 | S | D | 19,775 | $19.03 | 600,997 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive. (F1) Includes 552,729 unvested RSUs. |
| 4 | Common | Common Stock | 2024-01-04 | S | D | 38,301 | $19.05 | 584,971 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive. (F1) Includes 552,729 unvested RSUs. |
| 5 | Common | Common Stock | 2024-01-04 | M | A | 18,536 | $1.03 | 603,507 | D | — | — | (F1) Includes 552,729 unvested RSUs. |
| 6 | Common | Common Stock | 2024-01-04 | M | A | 200,000 | $5.54 | 803,507 | D | — | — | (F1) Includes 552,729 unvested RSUs. |
| 7 | Common | Common Stock | 2024-01-04 | S | D | 180,235 | $18.40 | 623,272 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.93, inclusive. (F1) Includes 552,729 unvested RSUs. |
| 8 | Common | Common Stock | 2024-01-03 | S | D | 16,026 | $20.50 | 584,971 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.50 to $20.58, inclusive. (F1) Includes 552,729 unvested RSUs. |
| 9 | Derivative | Stock option (right to buy) | 2024-01-03 | M | D | 51,183 | $0.00 | 18,536 | D | $1.03 · — to 2030-01-05 | 51,183 Common Stock | (F7) The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter. |
| 10 | Derivative | Stock option (right to buy) | 2024-01-04 | M | D | 18,536 | $0.00 | 0 | D | $1.03 · — to 2030-01-05 | 18,536 Common Stock | (F7) The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter. |
| 11 | Derivative | Stock option (right to buy) | 2024-01-04 | M | D | 200,000 | $0.00 | 107,863 | D | $5.54 · — to 2030-07-30 | 200,000 Common Stock | (F8) The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024. |